Classic Hodgkin Lymphoma
Conditions
Brief summary
This is a phase I/II study. All subjects are patients diagnosed with relapse or refractory (R/R) classic Hodgkin lymphoma (cHL) and has progressed on treatment with PD-1/L1 inhibitor therapy. The purpose of this study is to evaluate the safety and efficacy of AK129 (bispecific antibody targeting LAG-3 and PD-1) monotherapy or in combination with AK117 (anti-CD47 monoclonal antibody) in R/R cHL with PD-1/L1 inhibitor treatment failure.
Interventions
DRUGAK129
Subjects receive AK129 intravenously.
DRUGAK117
Subjects receive AK117 intravenously.
Sponsors
Akeso
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old at the time of enrolment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Expected Survival of ≥ 12 weeks. * Diagnosed as R/R cHL according to Lugano 2014 criteria. * Has progressed on treatment with PD-1/L1 inhibitior therapy. * Has adequate organ function. * All female and male subjects of reproductive potential must agree to use an effective method of contraception from the start of screening until 120 days after the last dose of study treatment.
Exclusion criteria
* Diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) or gray zone lymphoma. * Central nervous system (CNS) lymphoma involvement. * Known history of human T-cell leukemia virus type 1 (HTLV-1) infection. * Autologous hematopoietic stem cell transplantation (auto-HSCT) or chimeric antigen receptor T cell immunotherapy (CAR-T) within 90 days prior to the first dose of study treatment. * Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation (allo-HSCT). * Previous use of any agents targeting the CD47-SIRPα pathway, LAG-3 pathway, or similar targets. * Has other malignancies within 3 years prior to the first dose or residual lesions from other malignancies diagnosed more than 3 years ago. * Has an active autoimmune disease requiring systemic treatment within 2 years prior to the first dose. * History of active or previously confirmed inflammatory bowel disease. * History of interstitial lung disease requiring corticosteroid therapy, or current interstitial lung disease. * Has known active Hepatitis B or Hepatitis C. * Unresolved toxicity from previous anti-tumor treatment. * Uncontrolled comorbidities.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase I: Number of participants with dose limiting toxicity (DLT) | Within the first 28 days following the first dose of study treatment. | Any untoward medical occurrence in a subject within the first 28 days following the first dose, considered related to the study treatment. |
| Phase I/II: Incidence and severity of adverse events (AEs) | Up to approximately 2 years. | Any untoward medical occurrence in a subject, temporally associated with the use of study treatment, whether or not considered related to the study treatment. |
| Phase I/II: Objective response rate (ORR) | Up to approximately 2 years | The proportion of subjects achieving complete response (CR) or partial response (PR) assessed by investigator per Lugano 2014 criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | Up to approximately 2 years | The time from C1D1 until disease progression assessed by investigator or death due to any cause, whichever occurs first. |
| Overall survival (OS) | Up to approximately 2 years | The time from C1D1 until death due to any cause. |
| Maximum concentration (Cmax) | Up to approximately 2 years | The maximum concentration of the drug observed in the blood plasma after administration. |
| Disease control rate (DCR) | Up to approximately 2 years | The proportion of subjects achieving complete response (CR) , partial response (PR) or stable disease (SD) assessed by investigator per Lugano 2014 criteria. |
| Area under the curve (AUC) | Up to approximately 2 years | The area under the plasma concentration versus time curve, which represents the total drug exposure over time. |
| Half-life (T1/2) | Up to approximately 2 years | The time required for the plasma concentration of the drug to decrease by half. |
| Anti-drug antibody (ADA) | Up to approximately 2 years | Number of subjects with detectable anti-drug antibodies. |
| Time to maximum concentration (Tmax) | Up to approximately 2 years | The time taken to reach the maximum concentration (Cmax) of the drug in the blood plasma. |
| Time to response (TTR) | Up to approximately 2 years | The time from cycle 1 day 1(C1D1) to the first recorded response assessed by investigator per Lugano 2014 criteria. |
| Duration of response (DoR) | Up to approximately 2 years | The time from the first recorded response until disease progression assessed by investigator or death due to any cause, whichever occurs first. |
Countries
China
Contacts
Primary ContactWenting Li, MD
Outcome results
None listed